2020
Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors
Brummitt SI, Kjemtrup AM, Harvey DJ, Petersen JM, Sexton C, Replogle A, Packham AE, Bloch EM, Barbour AG, Krause PJ, Green V, Smith WA. Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. PLOS ONE 2020, 15: e0243950. PMID: 33370341, PMCID: PMC7769429, DOI: 10.1371/journal.pone.0243950.Peer-Reviewed Original ResearchConceptsLyme diseaseBlood donorsB. miyamotoiB. burgdorferiEndemic countiesWestern blotBorrelia miyamotoiB. burgdorferi antibodiesAdult blood donorsBorrelia burgdorferiIgG Western blotBlood donor seraRisk of infectionELISA test systemBurgdorferi antibodiesDonor seraC6 ELISAClinical casesEquivocal samplesHuman casesDiseaseAntibodiesI. pacificus ticksMiyamotoiBurgdorferiParasite burden and red blood cell exchange transfusion for babesiosis
O'Bryan J, Gokhale A, Hendrickson JE, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. Journal Of Clinical Apheresis 2020, 36: 127-134. PMID: 33179803, PMCID: PMC9517950, DOI: 10.1002/jca.21853.Peer-Reviewed Original ResearchConceptsEnd-organ dysfunctionPeak parasitemia levelsRed blood cell exchange transfusionParasitemia levelsExchange transfusionPeak parasitemiaDisease severityParasite burdenYale-New Haven HospitalBabesia microti parasitemiaHigh-grade parasitemiaRetrospective chart reviewBabesia microti infectionNew Haven HospitalAntimicrobial agentsChart reviewHepatic dysfunctionPatient demographicsClinical statusMedian lengthLaboratory indicatorsMicroti infectionDegree of hemolysisNineteen subjectsDysfunction
2010
Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ. Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Clinical Infectious Diseases 2010, 50: 381-386. PMID: 20047477, DOI: 10.1086/649859.Peer-Reviewed Original ResearchConceptsDrug regimenB. microtiLevel of immunosuppressionBabesia microti infectionTreatment of babesiosisDrug-resistant strainsEmergence of resistanceActive babesiosisMicrobiologic relapseLaboratory abnormalitiesDrug regimensImmunocompromised patientsOptimal therapyTreatment failureDrug therapyMicroti infectionPatientsClinical case historiesDrug resistanceBabesia microtiInfectionRegimenMicrotiEventual developmentBabesiosis
2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis
2007
Serum Reactivity against Borrelia burgdorferi OspA in Patients with Rheumatoid Arthritis▿
Hsieh YF, Liu HW, Hsu TC, Wei J, Shih CM, Krause PJ, Tsay GJ. Serum Reactivity against Borrelia burgdorferi OspA in Patients with Rheumatoid Arthritis▿. MSphere 2007, 14: 1437-1441. PMID: 17881508, PMCID: PMC2168181, DOI: 10.1128/cvi.00151-07.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialAntigens, SurfaceArthritis, RheumatoidAutoimmune DiseasesBacterial Outer Membrane ProteinsBacterial VaccinesBlotting, WesternBorrelia burgdorferiEnzyme-Linked Immunosorbent AssayFemaleHumansLipoproteinsLyme DiseaseMaleMiddle AgedRecombinant Fusion ProteinsConceptsRheumatoid arthritis patientsRheumatoid arthritisOspA antigenArthritis patientsAutoimmune diseasesSerum reactivityLyme diseaseDisease Activity ScoreCommon clinical featuresLyme disease patientsSurface protein AArthritis correlatesSynovial histologyOuter surface protein ALyme arthritisActivity scoreClinical featuresDisease patientsSerum concentrationsSimilar pathogenesisHealthy subjectsPatientsArthritisDisease severityDisease
2003
Increasing health burden of human babesiosis in endemic sites.
KRAUSE PJ, McKay K, Gadbaw J, Christianson D, Closter L, Lepore T, TELFORD SR, Sikand V, Ryan R, Persing D, RADOLF JD, Spielman A, _ _. Increasing health burden of human babesiosis in endemic sites. American Journal Of Tropical Medicine And Hygiene 2003, 68: 431-6. PMID: 12875292, DOI: 10.4269/ajtmh.2003.68.431.Peer-Reviewed Original ResearchConceptsYears of ageEndemic sitesCommunity-based serosurveysClinical spectrumHealth burdenPeople 20Borrelial infectionHuman infectionsBabesial infectionMore older adultsBabesia microtiBabesial antigensOlder adultsHuman babesiosisYoung adultsInfectionBorrelia burgdorferiIncidenceThree-fourthsAdultsAgePrudence IslandSeroprevalenceSerosurveyHospital
2000
Atovaquone and Azithromycin for the Treatment of Babesiosis
Krause P, Lepore T, Sikand V, Gadbaw J, Burke G, Telford S, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A. Atovaquone and Azithromycin for the Treatment of Babesiosis. New England Journal Of Medicine 2000, 343: 1454-1458. PMID: 11078770, DOI: 10.1056/nejm200011163432004.Peer-Reviewed Original ResearchConceptsCommon adverse effectsTreatment of babesiosisAdverse reactionsAdverse effectsCourse of clindamycinRegimen of clindamycinStart of therapyMalaria-like illnessPromising alternative treatmentStandard treatmentAlternative treatmentRegimenClindamycinAzithromycinAtovaquoneMonthsDiarrheaTreatmentBabesiosisQuinineSymptomsSubjectsPercentDaysBabesia microti DNA